Bristol abatacept BLA rolling along
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Remaining sections of Bristol-Myers Squibb's rolling BLA for abatacept will be submitted in early 2005, the firm says. The rheumatoid arthritis biologic is part of FDA's Continuous Marketing Application Pilot 1 program, which provides for submission in "reviewable units." Complete nonclinical and clinical sections have already been filed, Bristol says...
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.